Service d'urologie

Equipe principale
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


691 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | ...
 
WITHDRAWN: The benefit of adopting Microultrasound in the prostate cancer imaging pathway : A lesion-by-lesion analysis.
Martel P., Rakauskas A., Dagher J., La Rosa S., Meuwly J.Y., Roth B., Valerio M. Progres en urologie. Peer-reviewed.
 
Risk Factors of Asymptomatic Kidney Stone Passage in Adults with Recurrent Kidney Stones.
Stritt K., Fuster D.G., Dhayat N.A., Bonny O., Faller N., Christe A., Taha A., Ochs V., Ortlieb N., Roth B. et al. Clinical journal of the American Society of Nephrology. Peer-reviewed.
 
The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial).
Derré L., Crettenand F., Grilo N., Stritt K., Kiss B., Tawadros T., Domingos-Pereira S., Roth B., Cerantola Y., Lucca I., 2024/10/17. Trials, 25 (1) p. 687. Peer-reviewed.
 
UROPOT: study protocol for a randomized, double-blind phase I/II trial for metabolism-based potentiation of antimicrobial prophylaxis in the urological tract.
Stritt K., Roth B., Masnada A., Hammann F., Jacot D., Domingos-Pereira S., Crettenand F., Bohner P., Sommer I., Bréat E. et al., 2024/10/15. Trials, 25 (1) p. 682. Peer-reviewed.
 
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
Kaufmann E., Aeppli S., Arnold W., Balermpas P., Beyer J., Bieri U., Cathomas R., de Bari B., Dressler M., Engeler D.S. et al., 2024/09/19. World journal of urology, 42 (1) p. 527. Peer-reviewed.
 
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy.
Martini A., Wever L., Soeterik TFW, Rakauskas A., Fankhauser C.D., Grogg J.B., Checcucci E., Amparore D., Haiquel L., Rodriguez-Sanchez L. et al., 2024/09. Prostate cancer and prostatic diseases, 27 (3) pp. 520-524. Peer-reviewed.
 
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Afferi L., Spahn M., Hayoz S., Strebel R.T., Rothschild S.I., Seifert H., Özdemir B.C., Kiss B., Maletzki P., Engeler D. et al., 2024/09. BJU international, 134 (3) pp. 388-397. Peer-reviewed.
 
Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy.
Pavlovic B., Bräutigam K., Dartiguenave F., Martel P., Rakauskas A., Cesson V., Veit M., Oechslin P., Gu A., Hermanns T. et al., 2024/08/05. Scientific reports, 14 (1) p. 18148. Peer-reviewed.
Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection.
Maurer J., Eugster P.J., Collins K., Vocat C., Oke J., Nicholson B., Rakauskas A., Grouzmann E., Valerio M., 2024/08. European urology open science, 66 pp. 12-15. Peer-reviewed.
Obesity-related pubis lymphedema enclosing genitalia: An atypical case of genital reconstruction.
Wurlod D.A., Meuli J., Favre-Bulle A., Grilo N., di Summa P.G., 2024/07. Urology case reports, 55 p. 102790. Peer-reviewed.
Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.
Cloître M., Benkhaled S., Boughdad S., Schaefer N., Prior J.O., Zeverino M., Berthold D., Tawadros T., Meuwly J.Y., Martel P. et al., 2024/05/31. Cancers, 16 (11). Peer-reviewed.
 
The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.
Sorce G., Stabile A., Pellegrino F., Mazzone E., Mattei A., Afferi L., Serni S., Minervini A., Roumiguiè M., Malavaud B. et al., 2024/04/22. World journal of urology, 42 (1) p. 248. Peer-reviewed.
Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy.
Blanc J., Ruggiero J., Lucca I., Arnold N., Kiss B., Roth B., 2024/04/02. Cancers, 16 (7). Peer-reviewed.
 
The Vitamin D Metabolite Diagnostic Ratio Associates With Phenotypic Traits of Idiopathic Hypercalciuria.
Dhayat N.A., Mattmann C., Seeger H., Ritter A., Ernandez T., Stoermann-Chopard C., Buchkremer F., Segerer S., Roth B., Wuerzner G. et al., 2024/04. Kidney international reports, 9 (4) pp. 1072-1082. Peer-reviewed.
Respiratory Complications after Cystectomy with Urinary Diversion: Avoidable Complications or Ineluctable Destiny?
Martinez Carrique S., Crettenand F., Stritt K., Bohner P., Grilo N., Rodrigues-Dias S., Roth B., Lucca I., 2024/03/10. Journal of clinical medicine, 13 (6). Peer-reviewed.
 
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT.
Ditonno F., Franco A., Manfredi C., Veccia A., Valerio M., Bukavina L., Zukowski L.B., Vourganti S., Stenzl A., Andriole G.L. et al., 2024/03. Prostate cancer and prostatic diseases, 27 (1) pp. 29-36. Peer-reviewed.
 
Lithiase rénale, un changement de paradigme? [Change in the prevention of kidney stones]
Derouet C., Kissling S., Roth B., Bonny O., Schwotzer N., 2024/02/28. Revue medicale suisse, 20 (863) pp. 436-440. Peer-reviewed.
Impact of Enhanced Recovery after Surgery<sup>®</sup> Protocol Compliance on Length of Stay, Bowel Recovery and Complications after Radical Cystectomy.
Grilo N., Crettenand F., Bohner P., Rodrigues Dias S.C., Cerantola Y., Lucca I., 2024/01/25. Diagnostics, 14 (3). Peer-reviewed.
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L., Lucca I., Cesson V., Bohner P., Crettenand F., Rodrigues-Dias S.C., Dartiguenave F., Masnada A., Teixeira-Pereira C., Benmerzoug S. et al., 2023/12/14. Journal for immunotherapy of cancer, 11 (12) pp. e008020. Peer-reviewed.
 
Correction to: Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions.
Martini A., Touzani A., Mazzone E., Roumiguié M., Marra G., Valerio M., Beauval J.B., Campi R., Minervini A., van den Berg RCN et al., 2023/12. Prostate cancer and prostatic diseases, 26 (4) p. 806. Peer-reviewed.
 
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
Deivasigamani S., Kotamarti S., Rastinehad A.R., Salas R.S., de la Rosette JJMCH, Lepor H., Pinto P., Ahmed H.U., Gill I., Klotz L. et al., 2023/12. European urology, 84 (6) pp. 547-560. Peer-reviewed.
 
Cancer de la vessie : un suivi personnalisé pour une prise en charge efficiente [Bladder cancer : a comprehensive follow-up for an efficient and personalized care]
Bohner P., Pal M., Crettenand F., Roth B., Lucca I., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2250-2253. Peer-reviewed.
 
Chirurgie robot-assistée en urologie fonctionnelle et reconstructive [Robotic-assisted laparoscopic surgeries in functional and reconstructive urology]
Germanou A., Perrin A., Grilo N., Valerio M., Windisch O., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2243-2246. Peer-reviewed.
 
Cystectomie radicale chez les patients gériatriques. Outils de dépistage des complications postopératoires [Radical cystectomy in the geriatric population. Tools for screening postoperative complications]
Reale S., Bohner P., Crettenand F., Roth B., Lucca I., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2247-2249. Peer-reviewed.
 
Les décisions de politique de santé n’ont pas toujours l’effet escompté. L’exemple de l’urologie.
Valerio M., Roth B., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2231-2232. Peer-reviewed.
 
Un registre des cystectomies de la Société suisse d’urologie pour une meilleure qualité chirurgicale [A Swiss Urological Society register of cystectomies to improve surgical quality]
Pal M., Bohner P., Crettenand F., Roth B., Lucca I., 2023/11/29. Revue medicale suisse, 19 (852) pp. 2254-2256. Peer-reviewed.
Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol.
Schaer S., Rakauskas A., Dagher J., La Rosa S., Pensa J., Brisbane W., Marks L., Kinnaird A., Abouassaly R., Klein E. et al., 2023/11. World journal of urology, 41 (11) pp. 3325-3331. Peer-reviewed.
Do Swiss urologists and Swiss internists screen themselves and their relatives for prostate cancer? A questionnaire study.
Scherer T.P., Saba K., Wettstein M.S., Lucca I., Mortezavi A., Waisbrod S., Aujesky D., Capaul R., Strebel R.T., 2023/09/14. Swiss medical weekly, 153 p. 40115. Peer-reviewed.
Reply to Beilstein, C.M.; Wuethrich, P.Y. Comment on "Crettenand et al. Is Continuous Wound Infiltration a Better Option for Postoperative Pain Management after Open Nephrectomy Compared to Thoracic Epidural Analgesia? J. Clin. Med. 2023, 12, 2974".
Crettenand F., Assayed-Leonardi N., Rohrer F., Martinez Carrique S., Roth B., 2023/09/12. Journal of clinical medicine, 12 (18) p. 5918. Peer-reviewed.
bTUNED: transcutaneous tibial nerve stimulation for neurogenic lower urinary tract dysfunction.
Stalder S.A., Gross O., Anderson C.E., Bachmann L.M., Baumann S., Birkhäuser V., Bywater M., Del Popolo G., Engeler D.S., Agrò E.F. et al., 2023/09. BJU international, 132 (3) pp. 343-352. Peer-reviewed.
Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review.
Antonelli L., Sebro K., Lahmar A., Black P.C., Ghodoussipour S., Hamilton-Reeves J.M., Shah J., Bente Thoft J., Lerner S.P., Llorente C. et al., 2023/07. European urology focus, 9 (4) pp. 631-636. Peer-reviewed.
Differences in the Food Consumption Between Kidney Stone Formers and Nonformers in the Swiss Kidney Stone Cohort.
Legay C., Haeusermann T., Pasquier J., Chatelan A., Fuster D.G., Dhayat N., Seeger H., Ritter A., Mohebbi N., Ernandez T. et al., 2023/07. Journal of renal nutrition, 33 (4) pp. 555-565. Peer-reviewed.
Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study.
Zattoni F., Marra G., Martini A., Kasivisvanathan V., Grummet J., Harkin T., Ploussard G., Olivier J., Chiu P.K., Valerio M. et al., 2023/07. European urology focus, 9 (4) pp. 621-628. Peer-reviewed.
 
Reply by Authors.
Martini A., Wever L., Soeterik TFW, Rakauskas A., Fankhauser C.D., Grogg J.B., Checcucci E., Amparore D., Haiquel L., Rodriguez-Sanchez L. et al., 2023/07. The Journal of urology, 210 (1) p. 127. Peer-reviewed.
Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma.
Martini A., Wever L., Soeterik TFW, Rakauskas A., Fankhauser C.D., Grogg J.B., Checcucci E., Amparore D., Haiquel L., Rodriguez-Sanchez L. et al., 2023/07. The Journal of urology, 210 (1) pp. 117-127. Peer-reviewed.
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R., Lozano L.E., Anastasio A., Lofek S., Mastelic-Gavillet B., Navarro Rodrigo B., Nguyen S., Dartiguenave F., Rodrigues-Dias S.C., Cesson V. et al., 2023/06/08. Cancers, 15 (12) p. 3114. Peer-reviewed.
 
The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management.
Sacco M., Gandaglia G., Aas K., Ceci F., Chiu P., Fankhauser C.D., Fournier G., Heiddeger I., Kasivisvanathan V., Kesch C. et al., 2023/06. Clinical genitourinary cancer, 21 (3) pp. 416.e1-416.e10. Peer-reviewed.
 
Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. Reply.
Fuster D.G., Bonny O., Roth B., 2023/05/25. The New England journal of medicine, 388 (21) pp. 2015-2016. Peer-reviewed.
Is Continuous Wound Infiltration a Better Option for Postoperative Pain Management after Open Nephrectomy Compared to Thoracic Epidural Analgesia?
Crettenand F., Assayed-Leonardi N., Rohrer F., Martinez Carrique S., Roth B., 2023/04/19. Journal of clinical medicine, 12 (8) p. 2974. Peer-reviewed.
Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
Mattana F., Muraglia L., Rajwa P., Zattoni F., Marra G., Chiu PKF, Heidegger I., Kasivisvanathan V., Kesch C.V., Olivier J. et al., 2023/04. European urology oncology, 6 (2) pp. 128-136. Peer-reviewed.
Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M., Valerio M., Mampuya A., Rakauskas A., Berthold D., Tawadros T., Meuwly J.Y., Heym L., Duclos F., Vallet V. et al., 2023/04/01. The British journal of radiology, 96 (1145) p. 20220803. Peer-reviewed.
 
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Rajwa P., Yanagisawa T., Heidegger I., Zattoni F., Marra G., Soeterik TFW, van den Bergh RCN, Valerio M., Ceci F., Kesch C.V. et al., 2023/03. Prostate cancer and prostatic diseases, 26 (1) pp. 170-179. Peer-reviewed.
 
Screening of visceral metastasis in castration-resistant prostate cancer: a cornerstone in personalized patient's care.
Grobet-Jeandin E., Valerio M., 2023/03. Prostate cancer and prostatic diseases, 26 (1) pp. 3-4. Peer-reviewed.
 
Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy.
Testart Dardel N., Isenborghs E., Valerio M., Michielin O., Schaefer N., 2023/03/01. Clinical nuclear medicine, 48 (3) pp. e151-e152. Peer-reviewed.
 
An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Reply.
Martini A., Valerio M., 2023/02. The Journal of urology, 209 (2) p. 325. Peer-reviewed.
The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenon.
Rakauskas A., Peters M., Ball D., Kim N.H., Ahmed H.U., Winkler M., Shah T.T., 2023/02. Urologic oncology, 41 (2) pp. 106.e9-e16. Peer-reviewed.
Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study.
Rakauskas A., Peters M., Martel P., van Rossum PSN, La Rosa S., Meuwly J.Y., Roth B., Valerio M., 2023. PloS one, 18 (1) pp. e0280262. Peer-reviewed.
The Swiss Kidney Stone Cohort: A Longitudinal, Multicentric, Observational Cohort to Study Course and Causes of Kidney Stone Disease in Switzerland.
Bonny O., Fuster D., Seeger H., Ernandez T., Buchkremer F., Wuerzner G., Dhayat N., Ritter A., Stoermann C., Segerer S. et al., 2023. Kidney & blood pressure research, 48 (1) pp. 194-201. Peer-reviewed.
Topography of Prostate Cancer Recurrence: A Single-centre Analysis of Salvage Radical Prostatectomy Specimens and Implications for Focal Salvage Treatments.
Marra G., Calleris G., Massari E., Vissio E., Molinaro L., Cassoni P., D'Agate D., Oderda M., Valerio M., Raskin Y. et al., 2023/01. European urology open science, 47 pp. 110-118. Peer-reviewed.
 
Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
Schneider A.K., Domingos-Pereira S., Cesson V., Polak L., Fallon P.G., Zhu J., Roth B., Nardelli-Haefliger D., Derré L., 2023. Frontiers in immunology, 14 p. 1335326. Peer-reviewed.
Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.
Domingos-Pereira S., Sathiyanadan K., Polak L., Haefliger J.A., Schmittnaegel M., Ries C.H., Jichlinski P., Roth B., Derré L., Nardelli-Haefliger D., 2022/12/21. International journal of molecular sciences, 24 (1) p. 123. Peer-reviewed.
Infections urinaires chez les patients avec dysfonction neurogène du bas appareil urinaire [Urinary tract infections in patients with neurogenic lower urinary tract dysfunction]
Martinez S., Roth B., Grilo N., Aleton É., 2022/11/30. Revue medicale suisse, 18 (806) pp. 2270-2273. Peer-reviewed.
Neuromodulation sacrée en urologie : indications, développements et résultats [Sacral neuromodulation in urology: Indications, advancements and outcomes]
Pal M., Assayed Leonardi N., Roth B., Grilo N., 2022/11/30. Revue medicale suisse, 18 (806) pp. 2278-2281. Peer-reviewed.
Qualité de vie ou prolongation de la vie à tout prix ? - Les priorités des patients sont souvent différentes de celles des médecins.
Benamran D., Roth B., 2022/11/30. Revue medicale suisse, 18 (806) pp. 2267-2268. Peer-reviewed.
Traitement chirurgical de l’incontinence urinaire d’effort chez l’homme [Surgical treatments for male stress urinary incontinence]
Stritt K., Reale S., Roth B., Grilo N., 2022/11/30. Revue medicale suisse, 18 (806) pp. 2282-2284. Peer-reviewed.
Is EDSS Enough to Predict Risk of Upper Urinary Tract Damage in Patients with Multiple Sclerosis?
Stritt K., Lucca I., Roth B., Grilo N., 2022/11/22. Biomedicines, 10 (12) p. 3001. Peer-reviewed.
 
Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines.
Stangl-Kremser J., Lambertini L., Di Maida F., Martinez-Fundichely A., Ferro M., Pradere B., Soria F., Albisinni S., Wu Z., Del Giudice F. et al., 2022/11. European urology focus, 8 (6) pp. 1622-1626. Peer-reviewed.
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I., Derré L., Cesson V., Bohner P., Crettenand F., Rodrigues-Dias S., Dartiguenave F., Masnada A., Texeira-Pereira C., Benmerzoug S. et al., 2022/11. European urology open science, 45 pp. 55-58. Peer-reviewed.
The importance of the urologist in male oncology fertility preservation.
Micol L.A., Adenubi F., Williamson E., Lane S., Mitchell R.T., Sangster P., 2022/11. BJU international, 130 (5) pp. 637-645. Peer-reviewed.
 
Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society.
Marra G., Laguna M.P., Walz J., Pavlovich C.P., Bianco F., Gregg J., Lebastchi A.H., Lepor H., Macek P., Rais-Bahrami S. et al., 2022/10. Minerva urology and nephrology, 74 (5) pp. 581-589. Peer-reviewed.
 
The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study.
Zattoni F., Marra G., Kasivisvanathan V., Grummet J., Nandurkar R., Ploussard G., Olivier J., Chiu P.K., Valerio M., Gontero P. et al., 2022/10. The Journal of urology, 208 (4) pp. 830-837. Peer-reviewed.
ERAS® protocol improves survival after radical cystectomy: A single-center cohort study.
Crettenand F., M'Baya O., Grilo N., Valerio M., Dartiguenave F., Cerantola Y., Roth B., Rouvé J.D., Blanc C., Lucca I., 2022/09/02. Medicine, 101 (35) pp. e30258. Peer-reviewed.
 
A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
Furrer M.A., Papa N., Luetolf S., Roth B., Cumberbatch M., Dorin Vartolomei M., Thomas B.C., Thoeny H.C., Seiler R., Thalmann G.N. et al., 2022/09. BJU international, 130 (3) pp. 306-313. Peer-reviewed.
Body contouring abdominoplasty for augmentation enterocystoplasty with continent cutaneous urinary diversion in an obese adolescent patient: A case report.
Meuli J.N., Grilo N., Roth B., di Summa P.G., 2022/09. Urology case reports, 44 p. 102145. Peer-reviewed.
 
Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update.
Vartolomei M.D., Ferro M., Roth B., Teoh J.Y., Gontero P., Shariat S.F., 2022/09/01. Current opinion in urology, 32 (5) pp. 575-583. Peer-reviewed.
Syndrome du casse-noisette : une cause d’hématurie inexpliquée [Nutcracker syndrome: a cause of unexplained hematuria]
Rousseau S., Lucca I., Selby K., 2022/08/24. Revue medicale suisse, 18 (792) pp. 1566-1569. Peer-reviewed.
 
Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362.
Soria F., Lucca I., Moschini M., Mathieu R., Rouprêt M., Karakiewicz P.I., Briganti A., Rink M., Gust K.M., Hassler M.R. et al., 2022/08. Urologic oncology, 40 (8) p. 387. Peer-reviewed.
Corrigendum: Is urology a gender-biased career choice? A survey-based study of the Italian medical students'; perception of specialties.
Reale S., Orecchia L., Ippoliti S., Pletto S., Pastore S., Germani S., Nardi A., Miano R., 2022/08. Frontiers in surgery, 9 p. 1014036. Peer-reviewed.
 
Re: Multiparametric Ultrasound Versus Multiparametric MRI To Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study.
Rakauskas A., Valerio M., Roth B., 2022/08. European urology, 82 (2) pp. 239-240. Peer-reviewed.
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S., Chevalier M.F., Benmerzoug S., Cesson V., Schneider A.K., Rodrigues-Dias S.C., Dartiguenave F., Lucca I., Jichlinski P., Roth B. et al., 2022/08. Journal for immunotherapy of cancer, 10 (8) pp. e004880. Peer-reviewed.
Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.
Moreo E., Uranga S., Picó A., Gómez A.B., Nardelli-Haefliger D., Del Fresno C., Murillo I., Puentes E., Rodríguez E., Vales-Gómez M. et al., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004325. Peer-reviewed.
 
The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidée par micro-échographie, quel bénéfice ? Une analyse lésion par lésion.
Martel P., Rakauskas A., Dagher J., La Rosa S., Meuwly J.Y., Roth B., Valerio M., 2022/06. Progres en urologie, 32 (6S1) pp. 6S26-6S32. Peer-reviewed.
Nachsorge nach Steinsanierung bei Urolithiasis [Follow-up after urolithiasis management]
Stritt K., Bosshard P., Roth B., 2022/05. Der Urologe. Ausg. A, 61 (5) pp. 500-507. Peer-reviewed.
 
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S., Chevalier M.F., Verardo M., Nguyen S., Cesson V., Schneider A.K., Dartiguenave F., Rodrigues-Dias S.C., Lucca I., Jichlinski P. et al., 2022/05. European urology focus, 8 (3) pp. 748-751. Peer-reviewed.
 
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch C.A., Thalmann G.N., Lucca I., Kwiatkowski M., Wirth G.J., Strebel R.T., Engeler D., Pedrazzini A., Hüttenbrink C., Schultze-Seemann W. et al., 2022/04. European urology oncology, 5 (2) pp. 195-202. Peer-reviewed.
 
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
Reddy D., Peters M., Shah T.T., van Son M., Tanaka M.B., Huber P.M., Lomas D., Rakauskas A., Miah S., Eldred-Evans D. et al., 2022/04. European urology, 81 (4) pp. 407-413. Peer-reviewed.
 
Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions.
Martini A., Touzani A., Mazzone E., Roumiguié M., Marra G., Valerio M., Beauval J.B., Campi R., Minervini A., van den Berg RCN et al., 2022/04. Prostate cancer and prostatic diseases, 25 (4) pp. 794-796. Peer-reviewed.
Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth.
Sathiyanadan K., Alonso F., Domingos-Pereira S., Santoro T., Hamard L., Cesson V., Meda P., Nardelli-Haefliger D., Haefliger J.A., 2022/03/08. International journal of molecular sciences, 23 (6) p. 2930. Peer-reviewed.
Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer.
Alijaj N., Pavlovic B., Martel P., Rakauskas A., Cesson V., Saba K., Hermanns T., Oechslin P., Veit M., Provenzano M. et al., 2022/02/23. Cancers, 14 (5) p. 1135. Peer-reviewed.
 
An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
Martini A., Soeterik TFW, Haverdings H., Rahota R.G., Checcucci E., De Cillis S., Hermanns T., Fankhauser C.D., Afferi L., Moschini M. et al., 2022/02. The Journal of urology, 207 (2) pp. 350-357. Peer-reviewed.
 
Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
Mazzone E., Gandaglia G., Ploussard G., Marra G., Valerio M., Campi R., Mari A., Minervini A., Serni S., Moschini M. et al., 2022/02. European urology, 81 (2) pp. 193-203. Peer-reviewed.
 
An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
Hopstaken J.S., Bomers JGR, Sedelaar MJP, Valerio M., Fütterer J.J., Rovers M.M., 2022/01. European urology, 81 (1) pp. 5-33. Peer-reviewed.
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.
Heidegger I., Kesch C., Kretschmer A., Tsaur I., Ceci F., Valerio M., Tilki D., Marra G., Preisser F., Fankhauser C.D. et al., 2022. Therapeutic advances in medical oncology, 14 p. 17588359221081922. Peer-reviewed.
 
Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence.
Laine C., Gandaglia G., Valerio M., Heidegger I., Tsaur I., Olivier J., Ceci F., van den Bergh RCN, Kretschmer A., Thibault C. et al., 2022/01/01. Current opinion in urology, 32 (1) pp. 69-84. Peer-reviewed.
 
Incontinence urinaire: un bon diagnostic comme base de traitement [Urinary incontinence: a good diagnosis as a basis for treatment]
Martinez S., Martel P., Roth B., Grilo N., 2022/01. Praxis, 110 (1) pp. 32-37. Peer-reviewed.
Is Urology a gender-biased career choice? A survey-based study of the Italian medical students' perception of specialties.
Sofia R., Luca O., Simona I., Simone P., Serena P., Stefano G., Alessandra N., Roberto M., 2022. Frontiers in surgery, 9 p. 962824. Peer-reviewed.
 
The impact of stenting prior to oral chemolysis of upper urinary tract uric acid stones.
Tsaturyan A., Bosshard P., Bokova E., Bonny O., Stritt K., Roth B., 2022/01. International urology and nephrology, 54 (1) pp. 37-45. Peer-reviewed.
The SAFE Pilot Trial-SAlvage Focal Irreversible Electroporation-For Recurrent Localized Prostate Cancer: Rationale and Study Protocol.
Marra G., Shah T.T., D'Agate D., Marquis A., Calleris G., Lunelli L., Filippini C., Oderda M., Gatti M., Valerio M. et al., 2022. Frontiers in surgery, 9 p. 900528. Peer-reviewed.
Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives.
Kretschmer A., van den Bergh RCN, Martini A., Marra G., Valerio M., Tsaur I., Heidegger I., Kasivisvanathan V., Kesch C., Preisser F. et al., 2021/12/29. Cancers, 14 (1) p. 147. Peer-reviewed.
Infirmière clinicienne de centre du cancer : l’expérience du Centre de la prostate du CHUV [Cancer center clinical nurse: The experience of the CHUV Prostate Cancer Center]
Codeluppi C., Ninane F., Jolliet L., Glemarec P., Orcurto A., Rakauskas A., Tawadros T., Bosshard P., Eicher M., Herrera F. et al., 2021/12/01. Revue medicale suisse, 17 (761) pp. 2082-2085. Peer-reviewed.
Les biomarqueurs émergents du cancer de la prostate [Emerging biomarkers of prostate cancer]
Rakauskas A., Martel P., Roth B., Valerio M., 2021/12/01. Revue medicale suisse, 17 (761) pp. 2078-2081. Peer-reviewed.
L’urologie du futur []
Iselin C., Roth B., 2021/12/01. Revue medicale suisse, 17 (761) pp. 2071-2072. Peer-reviewed.
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S., Chevalier M.F., Villier L., Nguyen S., Cesson V., Schneider A.K., Dartiguenave F., Rodrigues-Dias S.C., Lucca I., Jichlinski P. et al., 2021/12. European urology open science, 34 pp. 79-82. Peer-reviewed.
Traitement de l’hyperplasie bénigne de la prostate - Alternatives chirurgicales à la résection transurétrale de la prostate [Benign prostatic hyperplasia treatment: Surgical alternatives to transurethral resection of the prostate]
Stritt K., Bosshard P., Roth B., Valerio M., Rakauskas A., 2021/12/01. Revue medicale suisse, 17 (761) pp. 2074-2076. Peer-reviewed.
 
Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate.
Kretschmer A., Mazzone E., Barletta F., Leni R., Heidegger I., Tsaur I., van den Bergh RCN, Valerio M., Marra G., Kasivisvanathan V. et al., 2021/11. European urology focus, 7 (6) pp. 1247-1253. Peer-reviewed.
 
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I., Necchi A., Pircher A., Tsaur I., Marra G., Kasivisvanathan V., Kretschmer A., Mathieu R., Ceci F., van den Bergh RCN et al., 2021/10. European urology oncology, 4 (5) pp. 745-754. Peer-reviewed.
 
Routine Preoperative Bone Scintigraphy Has Limited Impact on the Management of Patients with Invasive Bladder Cancer.
Furrer M.A., Grueter T., Bosshard P., Vartolomei M.D., Kiss B., Thalmann G.N., Roth B., 2021/09. European urology focus, 7 (5) pp. 1052-1060. Peer-reviewed.
Swiss germ-cell cancer consensus recommendations.
Beyer J., Berthold D., Bode P.K., Cathomas R., Fankhauser C.D., Fischer S., Gillessen S., Gross T., Hermanns T., Honecker F. et al., 2021/08/23. Swiss medical weekly, 151 (33-34) pp. w30023. Peer-reviewed.
Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A., Tawadros T., Lucca I., Herrera F., Bourhis J., Burruni R., Gomes M.N., Codeluppi C., Jolliet L., La Rosa S. et al., 2021/07. Investigative and clinical urology, 62 (4) pp. 416-422. Peer-reviewed.
 
Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer.
Surcel C., Mirvald C., Tsaur I., Borgmann H., Heidegger I., Labanaris A.P., Sinescu I., Tilki D., Ploussard G., Briganti A. et al., 2021/07. World journal of urology, 39 (7) pp. 2483-2490. Peer-reviewed.
 
Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.
Kretschmer A., Ploussard G., Heidegger I., Tsaur I., Borgmann H., Surcel C., Mathieu R., de Visschere P., Valerio M., van den Bergh RCN et al., 2021/07. European urology focus, 7 (4) pp. 742-751. Peer-reviewed.
 
3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction.
Amparore D., Fiori C., Valerio M., Schulman C., Giannakis I., De Cillis S., Kadner G., Porpiglia F., 2021/06. Prostate cancer and prostatic diseases, 24 (2) pp. 349-357. Peer-reviewed.
 
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study.
Shah T.T., Reddy D., Peters M., Ball D., Kim N.H., Gomez E.G., Miah S., Evans D.E., Guillaumier S., van Rossum PSN et al., 2021/06. Prostate cancer and prostatic diseases, 24 (2) pp. 567-574. Peer-reviewed.
 
Metabolische Abklärung von Nierensteinen [Metabolic investigation of stone formers]
Bonny O., Bosshard P., 2021/06. Therapeutische Umschau. Revue therapeutique, 78 (5) pp. 235-240. Peer-reviewed.
Robot-assisted Supratrigonal Cystectomy and Augmentation Cystoplasty with Totally Intracorporeal Reconstruction in Neurourological Patients: Technique Description and Preliminary Results.
Grilo N., Chartier-Kastler E., Grande P., Crettenand F., Parra J., Phé V., 2021/06. European urology, 79 (6) pp. 858-865. Peer-reviewed.
 
Seminal Vesical Sparing Cystectomy for Bladder Cancer is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study.
Furrer M.A., Kiss B., Studer U.E., Wuethrich P.Y., Gahl B., Seiler R., Roth B., Bosshard P., Thomas B.C., Burkhard F.C. et al., 2021/06. The Journal of urology, 205 (6) pp. 1629-1640. Peer-reviewed.
Clear cell renal cancer metastasis in the contralateral ureter: a case report.
Blanc J., Roth B., 2021/05/30. Journal of medical case reports, 15 (1) p. 309. Peer-reviewed.
 
The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.
Perrin A., Venderink W., Patak M.A., Möckel C., Fehr J.L., Jichlinski P., Porcellini B., Lucca I., Futterer J., Valerio M., 2021/05. Urologic oncology, 39 (5) pp. 297.e9-297.e16. Peer-reviewed.
Endoscopic treatment of spinal arachnoid cysts.
Papadimitiou K., Cossu G., Maduri R., Valerio M., Vamadevan S., Daniel R.T., Messerer M., 2021/04. Heliyon, 7 (4) pp. e06736. Peer-reviewed.
 
Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer.
Shah T.T., Peters M., Miah S., Eldred-Evans D., Yap T., Hosking-Jervis F., Dudderidge T., Hindley R.G., McCracken S., Greene D. et al., 2021/03. European urology focus, 7 (2) pp. 301-308. Peer-reviewed.
 
Human primed ILCPs support endothelial activation through NF-κB signaling.
Vanoni G., Ercolano G., Candiani S., Rutigliani M., Lanata M., Derré L., Marcenaro E., Schneider P., Romero P., Jandus C. et al., 2021/02/08. eLife, 10 pp. e58838. Peer-reviewed.
Focal Therapy for Prostate Cancer: Complications and Their Treatment.
Rakauskas A., Marra G., Heidegger I., Kasivisvanathan V., Kretschmer A., Zattoni F., Preisser F., Tilki D., Tsaur I., van den Bergh R. et al., 2021. Frontiers in surgery, 8 p. 696242. Peer-reviewed.
Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?
Zattoni F., Heidegger I., Kasivisvanathan V., Kretschmer A., Marra G., Magli A., Preisser F., Tilki D., Tsaur I., Valerio M. et al., 2021. Frontiers in surgery, 8 p. 691473. Peer-reviewed.
Radical Prostatectomy: Sequelae in the Course of Time.
Kesch C., Heidegger I., Kasivisvanathan V., Kretschmer A., Marra G., Preisser F., Tilki D., Tsaur I., Valerio M., van den Bergh RCN et al., 2021. Frontiers in surgery, 8 p. 684088. Peer-reviewed.
Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model
Domingos-Pereira Sonia, Roh Vincent, Hiou-Feige Agnès, Galliverti Gabriele, Simon Christian, Tolstonog Genrich V., Nardelli-Haefliger Denise, 2021/01/01. OncoImmunology, 10 (1) p. 1912473.
En période de pénurie de ressources pour la chirurgie élective, la prévention passe au premier plan []
Roth B., Iselin C., 2020/12/02. Revue medicale suisse, 16 (717) p. 2315. Peer-reviewed.
La néphrolithotomie percutanée comme traitement des néphrolithiases : l’expérience du CHUV [Percutaneous nephrolithotomy (PNL) in the treatment of nephrolithiasis: the CHUV experience]
Bacchetta F., M'baya O., Bosshard P., Roth B., 2020/12/02. Revue medicale suisse, 16 (717) pp. 2325-2329. Peer-reviewed.
Prise en charge de la lithiase urétérale [Overview of ureteral stone management]
Bosshard P., Stritt K., Roth B., 2020/12/02. Revue medicale suisse, 16 (717) pp. 2321-2324. Peer-reviewed.
Prévention de la lithiase urinaire – Résultats préliminaires de la Cohorte suisse des patients souffrant de calculs rénaux et de l’étude NOSTONE [Prevention of nephrolithiasis - Preliminary results of the Swiss Kidney Stone Cohort (SKSC) and the NOSTONE trial]
Stritt K., Bosshard P., Bonny O., Roth B., 2020/12/02. Revue medicale suisse, 16 (717) pp. 2317-2320. Peer-reviewed.
Oral chemolysis is an effective, non-invasive therapy for urinary stones suspected of uric acid content.
Tsaturyan A., Bokova E., Bosshard P., Bonny O., Fuster D.G., Roth B., 2020/12. Urolithiasis, 48 (6) pp. 501-507. Peer-reviewed.
 
Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G., Ploussard G., Valerio M., Marra G., Moschini M., Martini A., Roumiguié M., Fossati N., Stabile A., Beauval J.B. et al., 2020/12. European urology oncology, 3 (6) pp. 739-747. Peer-reviewed.
 
Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.
Kadner G., Valerio M., Giannakis I., Manit A., Lumen N., Ho BSH, Alonso S., Schulman C., Barber N., Amparore D. et al., 2020/12. World journal of urology, 38 (12) pp. 3235-3244. Peer-reviewed.
 
A treatment strategy to help select patients who may not need secondary intervention to remove symptomatic ureteral stones after previous stenting.
Stojkova Gafner E., Grüter T., Furrer M.A., Bosshard P., Kiss B., Vartolomei M.D., Roth B., 2020/11. World journal of urology, 38 (11) pp. 2955-2961. Peer-reviewed.
 
Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis.
Williams S.B., Cumberbatch MGK, Kamat A.M., Jubber I., Kerr P.S., McGrath J.S., Djaladat H., Collins J.W., Packiam V.T., Steinberg G.D. et al., 2020/11. European urology, 78 (5) pp. 719-730. Peer-reviewed.
 
Silica-related diseases in the modern world: A role for self-DNA sensing in lung inflammatory diseases.
Togbe D., Benmerzoug S., Jacobs M., Ryffel B., Quesniaux VFJ, 2020/11. Allergy, 75 (11) pp. 3009-3010. Peer-reviewed.
 
The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer.
Bacchetta F., Martins M., Regusci S., Jichlinski P., Meuwly J.Y., Lucca I., Valerio M., 2020/11. Urologic oncology, 38 (11) pp. 846.e1-846.e7. Peer-reviewed.
 
Editorial Comment.
Valerio M., 2020/10. The Journal of urology, 204 (4) p. 747. Peer-reviewed.
 
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
Marra G., Valerio M., Heidegger I., Tsaur I., Mathieu R., Ceci F., Ploussard G., van den Bergh RCN, Kretschmer A., Thibault C. et al., 2020/10. European urology oncology, 3 (5) pp. 565-581. Peer-reviewed.
 
Comparison of the Diagnostic Performance of Contrast-enhanced Ultrasound with That of Contrast-enhanced Computed Tomography and Contrast-enhanced Magnetic Resonance Imaging in the Evaluation of Renal Masses: A Systematic Review and Meta-analysis.
Furrer M.A., Spycher SCJ, Büttiker S.M., Gross T., Bosshard P., Thalmann G.N., Schneider M.P., Roth B., 2020/08. European urology oncology, 3 (4) pp. 464-473. Peer-reviewed.
 
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.
Gandaglia G., Martini A., Ploussard G., Fossati N., Stabile A., De Visschere P., Borgmann H., Heidegger I., Steinkohl F., Kretschmer A. et al., 2020/08. European urology, 78 (2) pp. 138-142. Peer-reviewed.
 
Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009.
van den Bergh RCN, Valerio M., Tilki D., Gandaglia G., EAU-YAU Prostate Cancer Working Party, 2020/08. European urology, 78 (2) pp. e67-e68. Peer-reviewed.
 
Targeting connexin37 alters angiogenesis and arteriovenous differentiation in the developing mouse retina.
Hamard L., Santoro T., Allagnat F., Meda P., Nardelli-Haefliger D., Alonso F., Haefliger J.A., 2020/06. FASEB journal, 34 (6) pp. 8234-8249. Peer-reviewed.
 
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer.
Mokkapati S., Porten S.P., Narayan V.M., Lim A.H., Jayaratna I.S., Roth B., Cheng T., Navai N., Wszolek M., Melquist J. et al., 2020/06. Molecular cancer research, 18 (6) pp. 811-821. Peer-reviewed.
 
The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Gandaglia G., Ploussard G., Valerio M., Mattei A., Fiori C., Roumiguié M., Fossati N., Stabile A., Beauval J.B., Malavaud B. et al., 2020/06. European urology, 77 (6) pp. 733-741. Peer-reviewed.
 
Identification of ureteral stones at reduced radiation exposure: a pilot study comparing conventional versus digital low-dosage linear slot scanning (Lodox®) radiography.
Fiechter S., Geissbühler E., Bähler A., Obmann V., Meierhans S., Exadaktylos A.K., Christe A., Thalmann G.N., Roth B., 2020/04. World journal of urology, 38 (4) pp. 1065-1071. Peer-reviewed.
 
Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Salvage Robotic Radical Prostatectomy for Recurrent Prostate Cancer After Focal Therapy.
Marra G., Van Velthoven R., Valerio M., 2020/04. European urology, 77 (4) pp. e103-e104. Peer-reviewed.
 
Intramuscular Immunization Induces Antigen-specific Antibodies in Urine.
Derré L., Lucca I., Cesson V., Valerio M., Cerantola Y., Burruni R., Fritschi U., Gharbi D., Bobst M., Legris A.S. et al., 2020/03/15. European urology focus, 6 (2) pp. 280-283. Peer-reviewed.
 
Re: Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study.
Roth B., 2020/03. European urology, 77 (3) p. 391. Peer-reviewed.
 
ERAS for Major Urological Procedures: Evidence Synthesis and Recommendations
Crettenand François, Martel Paul, Lucca Ilaria, Daneshmand Siamak, Cerantola Yannick, 2020. pp. 421-431 dans Enhanced Recovery After Surgery, Springer International Publishing.
 
Evaluation of 24-h urine collection quality in the Swiss Kidney Stone Cohort-NCCR Kidney.CH
Legay C., Fuster D., Dhayat N. A., Seeger H., Ritter A., Ernandez T., Stoermann-Chopard C., Buchkremer F., Segerer S., Wuerzner G. et al., 2020. pp. 35S dans Abstracts of the cancelled 52nd Annual Meeting of the Swiss Society of Nephrology, Swiss Medical Weekly.
 
Reduction and follow-up of hospital discharge letter delay using Little's law.
Burruni R., Cuany B., Valerio M., Jichlinski P., Kulik G., 2019/12/31. International journal for quality in health care, 31 (10) pp. 787-792. Peer-reviewed.
 
Hereditary prostate cancer - Primetime for genetic testing?
Heidegger I., Tsaur I., Borgmann H., Surcel C., Kretschmer A., Mathieu R., Visschere P., Valerio M., van den Bergh RCN, Ost P. et al., 2019/12. Cancer treatment reviews, 81 p. 101927. Peer-reviewed.
Imaging modalities in synchronous oligometastatic prostate cancer.
Futterer J.J., Surcel C., van den Bergh R., Borgmann H., Briganti A., Gandaglia G., Kretschmer A., Ost P., Sooriakumaran P., Tilki D. et al., 2019/12. World journal of urology, 37 (12) pp. 2573-2583. Peer-reviewed.
Actualité du traitement chirurgical de l’incontinence urinaire d’effort chez la femme [Current surgical treatments for women with stress urinary incontinence]
Zbinden M., Stritt K., Jichlinski P., Grilo N., 2019/11/27. Revue medicale suisse, 15 (673) pp. 2186-2189. Peer-reviewed.
Chimiothérapie néoadjuvante à base de cisplatine du cancer de la vessie : bientôt dépassée ? [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]
Bosshard P., Roth B., 2019/11/27. Revue medicale suisse, 15 (673) pp. 2190-2194. Peer-reviewed.
Coût de la prise en charge du cancer : l’investissement en urologie est-il raisonnable ?
Iselin C., Jichlinski P., 2019/11/27. Revue medicale suisse, 15 (673) pp. 2183-2184. Peer-reviewed.
Prise en charge de cancers urologiques chez la population âgée : quels enjeux ? [Management of urologic cancers in elderly people : which implications ?]
Schaer S., Valerio M., Jichlinski P., Lucca I., 2019/11/27. Revue medicale suisse, 15 (673) pp. 2195-2197. Peer-reviewed.
 
Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis.
Vartolomei M.D., Iwata T., Roth B., Kimura S., Mathieu R., Ferro M., Shariat S.F., Seitz C., 2019/11. World journal of urology, 37 (11) pp. 2313-2324. Peer-reviewed.
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
 
Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
Ploussard G., Gandaglia G., Borgmann H., de Visschere P., Heidegger I., Kretschmer A., Mathieu R., Surcel C., Tilki D., Tsaur I. et al., 2019/10. European urology, 76 (4) pp. 493-504. Peer-reviewed.
 
Shorter Hospital Stay and Fewer Hospitalizations in Patients With Visible Hematuria on Direct Oral Anticoagulants Compared to on Vitamin K Antagonists.
Müller M., Bosshard F., Nagler M., Roth B., Exadaktylos A.K., Sauter T.C., 2019/10. Urology, 132 pp. 101-108. Peer-reviewed.
 
The multifaceted immune regulation of bladder cancer.
Schneider A.K., Chevalier M.F., Derré L., 2019/10. Nature reviews. Urology, 16 (10) pp. 613-630. Peer-reviewed.
 
Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
Schardt J., Roth B., Seiler R., 2019/09. World journal of urology, 37 (9) pp. 1759-1765. Peer-reviewed.
 
Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis.
Kasivisvanathan V., Stabile A., Neves J.B., Giganti F., Valerio M., Shanmugabavan Y., Clement K.D., Sarkar D., Philippou Y., Thurtle D. et al., 2019/09. European urology, 76 (3) pp. 284-303. Peer-reviewed.
 
Salvage Local Treatments After Focal Therapy for Prostate Cancer.
Marra G., Valerio M., Emberton M., Heidenreich A., Crook J.M., Bossi A., Pisters L.L., 2019/09. European urology oncology, 2 (5) pp. 526-538. Peer-reviewed.
 
Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
Schneider M.P., Tornic J., Sýkora R., Abo Youssef N., Mordasini L., Krhut J., Chartier-Kastler E., Davies M., Gajewski J., Schurch B. et al., 2019/08. Neurourology and urodynamics, 38 (6) pp. 1482-1491. Peer-reviewed.
 
Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
Shah T.T., Peters M., Eldred-Evans D., Miah S., Yap T., Faure-Walker N.A., Hosking-Jervis F., Thomas B., Dudderidge T., Hindley R.G. et al., 2019/07. European urology, 76 (1) pp. 98-105. Peer-reviewed.
 
Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria.
Lucca I., Hofbauer S.L., Haitel A., Susani M., Shariat S.F., Klatte T., De Martino M., 2019/07. Oncology letters, 18 (1) pp. 57-62. Peer-reviewed.
 
Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
Porpiglia F., Fiori C., Amparore D., Kadner G., Manit A., Valerio M., Nicolaas L., Ho BSH, Alonso S., Schulman C. et al., 2019/06. BJU international, 123 (6) pp. 1061-1069. Peer-reviewed.
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.
Domingos-Pereira S., Galliverti G., Hanahan D., Nardelli-Haefliger D., 2019/05/06. Journal for immunotherapy of cancer, 7 (1) p. 122. Peer-reviewed.
 
Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?
Tsaur I., Heidegger I., Kretschmer A., Borgmann H., Gandaglia G., Briganti A., de Visschere P., Mathieu R., Valerio M., van den Bergh R. et al., 2019/05. Cancer treatment reviews, 75 pp. 20-26. Peer-reviewed.
 
Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution.
Roth B., Furrer M.A., Giannakis I., Vartolomei M.D., Boxler S., Wuethrich P.Y., Burkhard F.C., Thalmann G.N., Kiss B., 2019/05. The Journal of urology, 201 (5) pp. 909-915. Peer-reviewed.
Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
Domingos-Pereira S., Sathiyanadan K., La Rosa S., Polák L., Chevalier M.F., Martel P., Hojeij R., Derré L., Haefliger J.A., Jichlinski P. et al., 2019/04. Cancer immunology research, 7 (4) pp. 621-629. Peer-reviewed.
 
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
Gandaglia G., Ploussard G., Valerio M., Mattei A., Fiori C., Fossati N., Stabile A., Beauval J.B., Malavaud B., Roumiguié M. et al., 2019/03. European urology, 75 (3) pp. 506-514. Peer-reviewed.
 
Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.
van den Bergh R., Gandaglia G., Tilki D., Borgmann H., Ost P., Surcel C., Valerio M., Sooriakumaran P., Salomon L., Briganti A. et al., 2019/03. European urology focus, 5 (2) pp. 171-178. Peer-reviewed.
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera F.G., Valerio M., Berthold D., Tawadros T., Meuwly J.Y., Vallet V., Baumgartner P., Thierry A.C., De Bari B., Jichlinski P. et al., 2019/02/01. International journal of radiation oncology, biology, physics, 103 (2) pp. 320-334. Peer-reviewed.
 
Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?
Marra G., Ploussard G., Futterer J., Valerio M., EAU-YAU Prostate Cancer Working Party, 2019/02. World journal of urology, 37 (2) pp. 277-287. Peer-reviewed.
 
Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?
Ploussard G., Borgmann H., Briganti A., de Visschere P., Fütterer J.J., Gandaglia G., Heidegger I., Kretschmer A., Mathieu R., Ost P. et al., 2019/02. World journal of urology, 37 (2) pp. 243-251. Peer-reviewed.
 
Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
Valerio M., Emberton M., Ahmed H.U., 2019/02. European urology, 75 (2) pp. e21-e22. Peer-reviewed.
 
The pro- and anti-tumor role of ILC2s.
Trabanelli S., Chevalier M.F., Derré L., Jandus C., 2019/02. Seminars in immunology, 41 p. 101276. Peer-reviewed.
 
Version courte des recommandations de la récupération ameliorée après chirurgie (RAAC) pour la cystectomie : mesures techniques [Short version of recommendations for enhanced recovery program (ERP) for cystectomy: Technical measures]
Poinas G., Blache J.L., Kassab-Chahmi D., Evrard P.L., Artus P.M., Alfonsi P., Rébillard X., Beaussier M., Cerantola Y., Coloby P. et al., 2019/02. Progres en urologie, 29 (2) pp. 63-75. Peer-reviewed.
 
Urologie [Urology in 2018]
Jichlinski P., 2019/01/16. Revue medicale suisse, 15 (634) pp. 167-169. Peer-reviewed.
A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling.
Kuncewicz K., Spodzieja M., Sieradzan A., Karczyńska A., Dąbrowska K., Dadlez M., Speiser D.E., Derre L., Rodziewicz-Motowidło S., 2019/01/11. Oncotarget, 10 (4) pp. 536-550. Peer-reviewed.
Double Positive CD4<sup>+</sup>CD8<sup>+</sup> T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization.
Bohner P., Chevalier M.F., Cesson V., Rodrigues-Dias S.C., Dartiguenave F., Burruni R., Tawadros T., Valerio M., Lucca I., Nardelli-Haefliger D. et al., 2019. Frontiers in immunology, 10 p. 622. Peer-reviewed.
 
Spoilt for Choice: A Survey of Current Practices of Surgical Urinary Stone Treatment and Adherence to Evidence-Based Guidelines among Swiss Urologists.
Betschart P., Zumstein V., Jichlinski P., Herrmann TRW, Knoll T., Engeler D.S., Müllhaupt G., Schmid H.P., Abt D., 2019. Urologia internationalis, 103 (3) pp. 357-363. Peer-reviewed.
Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial.
Dhayat N.A., Faller N., Bonny O., Mohebbi N., Ritter A., Pellegrini L., Bedino G., Schönholzer C., Venzin R.M., Hüsler C. et al., 2018/12/10. BMC nephrology, 19 (1) p. 349. Peer-reviewed.
 
Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey.
Marra G., Ploussard G., Ost P., De Visschere PJL, Briganti A., Gandaglia G., Tilki D., Surcel C.I., Tsaur I., Van Den Bergh RCN et al., 2018/12. Urologic oncology, 36 (12) pp. 529.e11-529.e22. Peer-reviewed.
 
Changement de pratique en urologie et dans le monde de la santé : les bienfaits de la prise de recul []
Jichlinski P., Iselin C.E., 2018/11/28. Revue medicale suisse, 14 (629) pp. 2147-2148. Peer-reviewed.
 
Chirurgie ambulatoire en urologie : il est temps d’en parler [Ambulatory surgery in urology]
Haverdings H., Vola F., Altwegg G., Chollet M., Jichlinski P., Lucca I., 2018/11/28. Revue medicale suisse, 14 (629) pp. 2164-2166. Peer-reviewed.
 
Indications à un bilan urodynamique et à une antibioprophylaxie avant celui-ci [About the indications to urodynamic studies and to a prior antibioprophylaxy]
Micol L.A., Rakauskas A., Schurch B., 2018/11/28. Revue medicale suisse, 14 (629) pp. 2167-2171. Peer-reviewed.
 
Réhabilitation améliorée après chirurgie urologique majeure : quel rôle pour le médecin généraliste ? [Improved rehabilitation after major urological surgery : what role for the general practitioner ?]
Martel P., Crettenand F., M'baya O., Cerantola Y., Jichlinski P., Lucca I., 2018/11/28. Revue medicale suisse, 14 (629) pp. 2150-2153. Peer-reviewed.
 
Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Chevalier M.F., Schneider A.K., Cesson V., Dartiguenave F., Lucca I., Jichlinski P., Nardelli-Haefliger D., Derré L., 2018/11. European urology, 74 (5) pp. 540-544. Peer-reviewed.
 
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Gandaglia G., van den Bergh RCN, Tilki D., Fossati N., Ost P., Surcel C.I., Sooriakumaran P., Tsaur I., Valerio M., Kretschmer A. et al., 2018/11. BJU international, 122 (5) pp. 823-830. Peer-reviewed.
 
Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
Galliverti G., Tichet M., Domingos-Pereira S., Hauert S., Nardelli-Haefliger D., Swartz M.A., Hanahan D., Wullschleger S., 2018/11. Cancer immunology research, 6 (11) pp. 1301-1313. Peer-reviewed.
 
Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology.
van den Bergh RCN, Ost P., Surcel C., Valerio M., Fütterer J.J., Gandaglia G., Sooriakumaran P., Tilki D., Tsaur I., Ploussard G. et al., 2018/09. World journal of urology, 36 (9) pp. 1489-1494. Peer-reviewed.
 
Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
Rentsch C.A., Derré L., Dugas S.G., Wetterauer C., Federer-Gsponer J.R., Thalmann G.N., Ingersoll M.A., 2018/07. European urology focus, 4 (4) pp. 485-493. Peer-reviewed.
 
Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer.
Alvarez-Arguedas S., Uranga S., Martín M., Elizalde J., Gomez A.B., Julián E., Nardelli-Haefliger D., Martín C., Aguilo N., 2018/07. Translational research, 197 pp. 32-42. Peer-reviewed.
 
New technologies and techniques for prostate cancer focal therapy.
Linares-Espinós E., Carneiro A., Martínez-Salamanca J.I., Bianco F., Castro-Alfaro A., Cathelineau X., Valerio M., Sanchez-Salas R., 2018/06. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 70 (3) pp. 252-263. Peer-reviewed.
 
Re: Effect of Prior Focal Therapy on Perioperative, Oncologic and Functional Outcomes of Salvage Robotic Assisted Radical Prostatectomy: I. Nunes-Silva, E. et al.
Shah T.T., Valerio M., Ahmed H.U., 2018/06. The Journal of urology, 199 (6) pp. 1634-1635. Peer-reviewed.
 
L’application d’un programme de réhabilitation précoce (ERAS) améliore-t-elle les résultats périopératoires après cystectomie ? [Do initial experience with an enhanced recovery program after surgery (ERAS) improve postoperative outcomes after cystectomy?]
Baldini A., Fassi Fehri H., Cerantola Y., Bayle F., Ravier E., Belot P.Y., Arnouil N., Colombel M., Badet L., 2018/05. Progres en urologie, 28 (6) pp. 351-358. Peer-reviewed.
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
 
Multiparametric prostate MRI: technical conduct, standardized report and clinical use.
Manfredi M., Mele F., Garrou D., Walz J., Fütterer J.J., Russo F., Vassallo L., Villers A., Emberton M., Valerio M., 2018/02. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 70 (1) pp. 9-21. Peer-reviewed.
 
Urologie [Urology]
Jichlinski P., 2018/01/10. Revue medicale suisse, 14 (588-589) pp. 97-99. Peer-reviewed.
 
An Accurate Diagnostic Pathway Helps to Correctly Distinguish Between the Possible Causes of Acute Scrotum.
Roth B., Giannakis I., Ricklin M.E., Thalmann G.N., Exadaktylos A.K., 2018/01. Oman medical journal, 33 (1) pp. 55-60. Peer-reviewed.
Occurrence and prognosis of lymph node metastases in patients selected for isolated limb perfusion with soft tissue sarcoma.
Crettenand F., Martin D., Cherix S., Demartines N., Matter M., 2018. Journal of Cancer, 9 (18) pp. 3311-3315. Peer-reviewed.
 
Testicular Estrogen-Secreting Leydig Cell Tumor in 18F-FDG PET/CT: An Incidental Detection in a Patient Treated by Chemotherapy for Hodgkin Lymphoma.
Van Der Gucht A., Maged Z., Burruni R., Barras J.L., Schaefer N., 2018/01. Clinical nuclear medicine, 43 (1) pp. 41-43. Peer-reviewed.
An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements.
Campelo S., Valerio M., Ahmed H.U., Hu Y., Arena S.L., Neal R.E., Emberton M., Arena C.B., 2017/12. APL bioengineering, 1 (1) p. 016101. Peer-reviewed.
 
Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence.
Kiss B., Furrer M.A., Wuethrich P.Y., Burkhard F.C., Thalmann G.N., Roth B., 2017/12. The Journal of urology, 198 (6) pp. 1263-1268. Peer-reviewed.
Ablation du cancer primaire dans les néoplasies urologiques oligométastatiques : évidence ou vœux pieux ? [Local treatment in oligometastatic urological malignancies : evidence of wishful thinking ?]
Valerio M., Cerantola Y., Lucca I., Berthold D., Jichlinski P., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2083-2086. Peer-reviewed.
 
Immunonutrition en uro-oncologie : entre mythe et réalité [Myths and reality about immunonutrition in uro-oncology]
Cerantola Y., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2079-2082. Peer-reviewed.
Immunothérapie : une révolution dans la prise en charge du cancer de la vessie ? [Immunotherapy : a revolution in the management of urothelial bladder cancer ?]
Adam S.M., Derré L., Jichlinski P., Lucca I., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2074-2078. Peer-reviewed.
 
Urologie évolutive : par X, Y et Z… et encore ! []
Iselin C.E., Jichlinski P., 2017/11/29. Revue medicale suisse, 13 (585) p. 2067. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University